Esperion Therapeutics | ESPR - Gross Profit On Sales


Esperion Therapeutics reported $140.59M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amarin USD 23.17M 961K Dec/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Cipla INR 41.64B 6.31B Dec/2025
CSL USD 4.46B 2.71B Dec/2025
Cytokinetics USD 17.76M 15.82M Dec/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Geron USD 46.71M 525K Dec/2025
Grifols EUR 766.49M 39.74M Dec/2024
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
Merck USD 13.42B 431M Sep/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Moderna USD 226M 583M Dec/2025
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
United Therapeutics USD 315.5M 286.6M Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024